Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum

被引:61
作者
Bychkov, Evgeny
Ahmed, M. Rafiuddin
Dalby, Kevin N.
Gurevich, Eugenia V.
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[2] Inst Human Brain, Lab Neuroimmunol, St Petersburg, Russia
[3] Univ Texas, Div Med Chem, Austin, TX 78712 USA
关键词
Parkinson's disease; 6-hydroxydopamine; L-DOPA; pergolide; extracellular signal-regulated kinase; serine/threonine protein kinase/protein kinase B;
D O I
10.1111/j.1471-4159.2007.04586.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dysregulation of signaling pathways is believed to contribute to Parkinson's disease pathology and L-DOPA-induced motor complications. Long-lived dopamine (DA) agonists are less likely to cause motor complications by virtue of continuous stimulation of DA receptors. In this study, we compared the effects of the unilateral 6-hydroxydopamine lesion and subsequent treatment with L-DOPA and DA agonist pergolide on signaling pathways in rats. Pergolide caused less pronounced behavioral sensitization than L-DOPA (25 mg/kg, i.p., 10 days), particularly at lower dose (0.5 and 0.25 mg/kg, i.p.). Pergolide, but not L-DOPA, reversed lesion-induced up-regulation of preproenkephalin and did not up-regulate preprodynorphine or DA D3 receptor in the lesioned hemisphere. Pergolide was as effective as L-DOPA in reversing the lesion-induced elevation of ERK2 phosphorylation in response to acute apomorphine administration (0.05 mg/kg, s.c.). Chronic L-DOPA significantly elevated the level of Akt phosphorylation at both Thr 308 and Ser 473 and concentration of phosphorylated GSK3 alpha, whereas pergolide suppressed the lesion- and/or challenge-induced supersensitive Akt responses. The data indicate that L-DOPA, unlike pergolide, exacerbates imbalances in the Akt pathway caused by the loss of DA. The results support the hypothesis that the Akt pathway is involved in longterm actions of L-DOPA and may be linked to L-DOPA-induced dyskinesia.
引用
收藏
页码:699 / 711
页数:13
相关论文
共 48 条
[1]   Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum [J].
Alimohamad, H ;
Rajakumar, N ;
Seah, YH ;
Rushlow, W .
BIOLOGICAL PSYCHIATRY, 2005, 57 (05) :533-542
[2]  
[Anonymous], RAT BRAIN STEREOTAXI
[3]   Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia [J].
Aubert, I ;
Guigoni, C ;
Håkansson, K ;
Li, Q ;
Dovero, S ;
Barthe, N ;
Bioulac, BH ;
Gross, CE ;
Fisone, G ;
Bloch, B ;
Bezard, E .
ANNALS OF NEUROLOGY, 2005, 57 (01) :17-26
[4]   Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade [J].
Beaulieu, JM ;
Sotnikova, TD ;
Yao, WD ;
Kockeritz, L ;
Woodgett, JR ;
Gainetdinov, RR ;
Caron, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (14) :5099-5104
[5]   An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior [J].
Beaulieu, JM ;
Sotnikova, TD ;
Marion, S ;
Lefkowitz, RJ ;
Gainetdinov, RR ;
Caron, MG .
CELL, 2005, 122 (02) :261-273
[6]   L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain [J].
Bezard, E ;
Gross, CE ;
Qin, L ;
Gurevich, VV ;
Benovic, JL ;
Gurevich, EV .
NEUROBIOLOGY OF DISEASE, 2005, 18 (02) :323-335
[7]   The pharmacokinetics of pergolide in Parkinson's disease [J].
Blin, O .
CURRENT OPINION IN NEUROLOGY, 2003, 16 :S9-S12
[8]   Comparing dopamine agonists in Parkinson's disease [J].
Bonuccelli, U .
CURRENT OPINION IN NEUROLOGY, 2003, 16 :S13-S19
[9]  
Bonuccelli Ubaldo, 2006, Expert Rev Neurother, V6, P81, DOI 10.1586/14737175.6.1.81
[10]   Induction of dopamine D-3 receptor expression as a mechanism of behavioral sensitization to levodopa [J].
Bordet, R ;
Ridray, S ;
Carbon, S ;
Diaz, J ;
Sokoloff, P ;
Schwartz, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :3363-3367